Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP7A1 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP7A1 Kits (42) and CYP7A1 Proteins (8) and many more products for this protein.
Showing 10 out of 39 products:
Human Polyclonal CYP7A1 Primary Antibody for IF (p), IHC (p) - ABIN739725
Gabbi, Bertolotti, Anzivino, Macchioni, Del Puppo, Ricchi, Carubbi, Tagliafico, Romagnoli, Odoardi, Loria, Losi, Carulli: Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. in Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2012
Show all 6 references for ABIN739725
Human Polyclonal CYP7A1 Primary Antibody for EIA, WB - ABIN360417
Lenícek, Komárek, Zimolová, Kovár, Jirsa, Lukás, Vítek: CYP7A1 promoter polymorphism -203A>C affects bile salt synthesis rate in patients after ileal resection. in Journal of lipid research 2008
Show all 2 references for ABIN360417
The finding that overexpression of HIF-1alpha (show HIF1A Antibodies) increased the activity of the CYP7A1 promoter suggested that hypoxia decreased the expression of CYP7A1 in a HIF-1 (show HIF1A Antibodies)-independent manner.
Macrophage cholesterol efflux in patients with type II diabetes mellitus was significantly reduced, and that this reduction was associated with the down-regulation of CYP7A1 expression.
CYP7A1 and APOE (show APOE Antibodies) isoform are associated with the extent of reduction in circulating LDL cholesterol in response to plant sterols consumption.
The CYP7A1 rs7833904 polymorphism may modify the risk of CAD (show CAD Antibodies).
The CYP7A1 crystallographic models identify residues involved in cholest-4-en-3 (show EN1 Antibodies)-one binding.
we identified for the first time a significant association of the A-204C polymorphism of the CYP7A1 gene and development of tuberculosis in a Moroccan population
The CYP7A1 -204A>C polymorphism is significantly associated with serum lipid levels in Asian population, but not gallbladder stone disease. [Meta-analysis]
Cyp7a1 is a direct Thyroid hormone receptor (show THRA Antibodies) (TR) target gene that responds to physiologic TR levels through a set of distinct response elements in its promoter.
Activation of the VDR (show CYP27B1 Antibodies) represses hepatic SHP (show LAMC1 Antibodies) to increase levels of CYP7A1 and reduce cholesterol.
Two known single nucleotide polymorphisms were identified in the 5'-UTR (show UTS2R Antibodies) of CYP7A1 and both were associated with neuromyelitis optica but not with Multiple sclerosis.
Mice deficient in cholesterol 7 alpha-hydroxylase, supplemented with chenodeoxycholic acid, have altered liver and intestinal bile acids.
Cholesterol lowering properties of oats involve increased production of bile acids via the classic pathway with up-regulation of CYP7A1 and CYP8B1 (show CYP8B1 Antibodies).
A CYP7A1/SREBP2 (show SREBF2 Antibodies)/miR (show MLXIP Antibodies)-33a axis plays a critical role in regulation of hepatic cholesterol, bile acid, and fatty acid synthesis.
Ileal Fibroblast Growth Factor-15 (FGF15) expression was significantly reduced in Asbt (show SLC10A2 Antibodies)(-/-)apoE (show APOE Antibodies)(-/-) mice and was inversely correlated with expression of hepatic cholesterol 7-hydroxylase (Cyp7a1).
HNF4alpha (show HNF4A Antibodies) and LRH-1 (show NR5A2 Antibodies) promote active transcription histone marks on the Cyp7a1 promoter that are reversed by FGF19 (show FGF19 Antibodies) in a SHP (show LAMC1 Antibodies)-dependent manner
these data suggest that FGF7 (show FGF7 Antibodies) is a novel regulator of CYP7A1 expression in hepatocytes and may prevent hepatocytes from accumulating toxic bile acids during liver injury and fibrosis.
Results indicate that although PPARgamma (show PPARG Antibodies) activation increased PCSK9 (show PCSK9 Antibodies) expression, PPARgamma (show PPARG Antibodies) activation induced LDLR (show LDLR Antibodies) and CYP7A1 expression that enhanced LDL cholesterol metabolism.
Cyanidin-3-O-beta-glucoside consumption reduced hypercholesterolemia, promoted fecal bile acid excretion and upregulated hepatic cholesterol 7a-hydroxylase expression (CYP7A1).
Chitosan oligosaccharides promote reverse cholesterol transport and expression of scavenger receptor BI and CYP7A1 in mice
the effect of polymorphism in the cholesterol 7-alpha hydroxylase gene locus and dietary cholesterol on cerebrum cholesterol in neonatal pigs fed sow's milk formulas are reported.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This endoplasmic reticulum membrane protein catalyzes the first reaction in the cholesterol catabolic pathway in the liver, which converts cholesterol to bile acids. This reaction is the rate limiting step and the major site of regulation of bile acid synthesis, which is the primary mechanism for the removal of cholesterol from the body. Polymorphisms in the promoter of this gene are associated with defects in bile acid synthesis.
, cholesterol 7-alpha-monooxygenase
, cytochrome P450 7A1
, cytochrome P450, subfamily VIIA polypeptide 1
, cholesterol 7 alpha hydroxylase
, cytochrome P450, 7a1
, cholesterol 7-alpha hydroxylase
, cytochrome P450 (cholesterol hydroxylase 7 alpha)
, cholesterol 7alpha-hydroxylase
, cholesterol 7 alpha-hydroxylase